FILING ANALYSIS · MONDAY, NOVEMBER 16
MapLight Therapeutics, Inc. MPLT — 8-K: Results of Operations and Financial Condition
neutral
MapLight Therapeutics reported a strong cash position of $463.4 million, which is expected to fund operations through key clinical readouts and through 2028, and announced plans to advance ML-007C-MA into a Phase 3 trial for schizophrenia and a Phase 2 trial for Alzheimer's disease psychosis, but no quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →